Skip to main content
Medical information Clinical review pending

Genetic Testing

IgVH Hypermutation Analysis Confirmatory Test

The IgVH Hypermutation Analysis Confirmatory Test helps diagnose and manage leukemia by analyzing genetic mutations in immunoglobulin heavy chain variable region (IgVH) genes. This test provides crucial insights for treatment decisions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
4 mL (2 mL minimum) of whole blood collected in a Lavender top (EDTA) tube.
Results
Approximately 10 days from sample collection. Confirm with the laboratory before booking.
Preparation
No special preparation is required for this test.
Test priceKSh 50,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the IgVH Hypermutation Analysis Confirmatory Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Suspected diagnosis of leukemia
  • ✓Monitoring leukemia progression
  • ✓Guiding treatment decisions in leukemia
  • ✓Evaluating prognosis in leukemia
  • ✓Patients with unexplained fatigue, weight loss, or frequent infections
  • ✓Individuals with a family history of hematologic malignancies
02

In plain language

What this test helps you understand

This test provides critical information for the accurate diagnosis, management, and prognosis of certain types of leukemia. It aids in determining the most effective treatment options based on the mutational status of IgVH genes and helps monitor disease progression and response to therapy.
The IgVH Hypermutation Analysis Confirmatory Test is a diagnostic tool used in hematology and oncology, particularly for patients suspected of having leukemia. It helps determine the mutational status of immunoglobulin heavy chain variable region (IgVH) genes, which can influence treatment and prognosis. This test detects hypermutations in the IgVH genes, often linked to the development and progression of certain leukemias. Analyzing these genetic alterations helps healthcare providers understand the nature of the leukemia and tailor treatment strategies. Patients exhibiting symptoms like unexplained fatigue, weight loss, or frequent infections, as well as those with a family history of hematologic malignancies, may benefit from this analysis. Results indicate the presence or absence of hypermutations, guiding therapeutic decisions and monitoring disease progression. Discuss your results with your healthcare provider for a full understanding.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is required for this test.
Sample4 mL (2 mL minimum) of whole blood collected in a Lavender top (EDTA) tube.
MethodologyNext Generation Sequencing (NGS) is used to analyze the IgVH gene region for hypermutations.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

IgVH hypermutation refers to changes in the immunoglobulin heavy chain variable region gene. These mutations are often associated with certain types of leukemia and can influence disease prognosis and treatment response.
This test is typically recommended for patients suspected of having leukemia, those monitoring their disease, or individuals needing guidance on treatment options based on their leukemia's genetic characteristics.
The sample required is a blood draw. 4 mL (2 mL minimum) of whole blood is collected in a Lavender top (EDTA) tube.
No special preparation is required for this test.
Results are typically available within approximately 10 days from the date the sample is received by the laboratory. Confirm with the laboratory before booking.
A healthcare provider will interpret the results in the context of your overall health and other diagnostic information. The presence or absence of IgVH hypermutations can provide important insights for diagnosis and treatment planning.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp